TetraLogic Pharmaceuticals Corporation TLOG
Set alert
At close · Oct 29
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.0002
- Prev close
- 0.0001
- Mkt cap
- 2.48K
- Vol
- 400
- Avg vol
- 256
- EPS
- -0.01
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0002
- High
- 0.0002
- Forward P/E
- -0.05
- Beta
- 2.56
- Short ratio
- 4.39
- Inst. own
- 27.10%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2016
- 50-d avg
- 0.084686
- 200-d avg
- 0.201812
- 1y target
- 1.00
2Y chart
Signals (12)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Sep 25, 2026 | 1 month ago |
| SMA: Bullish | Sep 4, 2026 | 1 month ago |
| RSI: Overbought | Sep 4, 2026 | 1 month ago |
| MACD: Buy Signal | Jun 4, 2026 | 4 months ago |
| MACD: Sell Signal | May 14, 2026 | 5 months ago |
| MACD: Buy Signal | Nov 4, 2025 | 12 months ago |
| SMA: Bearish | Oct 16, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 16, 2025 | 1 year ago |
| RSI: Oversold | Oct 16, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 7, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 20, 2025 | 1 year ago |
| RSI: Overbought | Aug 13, 2025 | 1 year ago |
Key statistics
- Market cap
- 1.22M
- Enterprise value
- 26.43M
- Trailing P/E
- -0.03
- Forward P/E
- -0.05
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -1.65
- Beta
- 2.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.20M
- Total cash
- 5.89M
- Total debt
- 30.83M
- Return on equity
- 0.00%
- Shares outstanding
- 24.47M
- Short % of float
- 7.12%
- 50-day average
- 0.084686
- 200-day average
- 0.201812
Analyst view
Consensus: buy
Next earnings
Nov 3, 2016
Expected Nov 3, 2016. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2016 | Sep 1, 2016 | 0.00 | — | — | — |
| Aug 11, 2016 | Jun 1, 2016 | 0.00 | -0.22 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 30, 2015 | ROTH Capital | init | — | Buy |
| Apr 8, 2014 | WBB Securities | up | Speculative Buy | Buy |
| Mar 9, 2014 | WBB Securities | init | — | Speculative Buy |
About TetraLogic Pharmaceuticals Corporation
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tetralogicpharma.com
News
Your note
Sign in to keep a note on TLOG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BUCHI J KEVIN | Officer | Purchase | Mar 25, 2015 | 330,714 |
| CLARUS LIFESCIENCES II, L.P. | Beneficial Owner (10% or more) | Sale | Feb 8, 2016 | 2,214,523 |
| HUTCHISON PATRICK | Officer | Ownership Statement | Apr 29, 2016 | 7,000 |
| MEYERS PETE A. | Officer | Purchase | Mar 26, 2015 | 153,891 |
| PECORA ANDREW L | Director | Purchase | Jul 9, 2015 | 184,830 |
| SCHMITT PAUL J | Director | Purchase | Jul 1, 2015 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 0.78% | 192,100 | 30.35K | Sep 29, 2016 |
| Vanguard Group, Inc. (The) | 0.64% | 157,349 | 24.86K | Sep 29, 2016 |
| KCG Holdings, Inc. | 0.44% | 109,634 | 17.32K | Sep 29, 2016 |
| Susquehanna International Group, LLP | 0.33% | 82,370 | 13.01K | Sep 29, 2016 |
| Geode Capital Management, LLC | 0.31% | 76,763 | 12.13K | Sep 29, 2016 |
| Goldman Sachs Group, Inc. | 0.18% | 44,131 | 6.97K | Sep 29, 2016 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.57% | 141,249 | 43.22K | Jun 29, 2016 |
| Fidelity Extended Market Index Fund | 0.26% | 63,792 | 14.16K | Aug 30, 2016 |
| Claymore ETF Tr-Wilshire Micro Cap ETF | 0.09% | 21,865 | 4.85K | Aug 30, 2016 |
| Fidelity Total Market Index Fund | 0.02% | 5,276 | 1.17K | Aug 30, 2016 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 4,788 | 1.06K | Aug 30, 2016 |
| Fidelity NASDAQ Composite Index Tracking Stock | 0.01% | 2,907 | 645 | Aug 30, 2016 |